Lung inflammatory pattern and antibiotic treatment in pneumonia

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Lorenzo, María José ^a,c   Moret, Inés ^a   Sarria, Benjamín ^b   Cases, Enrique ^a   Cortijo, Julio ^b,e   Méndez, Raúl ^a   Molina, Jose ^d   Gimeno, Alejandra ^a   Menéndez, Rosario ^a,d,e  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Community acquired pneumonia; Lung inflammation; Macrolides

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; CORTICOSTEROID; ERTAPENEM; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEVOFLOXACIN; LINEZOLID; MACROLIDE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ANTIINFECTIVE AGENT; AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BRONCHOSCOPY; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATION; LENGTH OF STAY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT RESPONSE; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CASE CONTROL STUDY; COMBINATION DRUG THERAPY; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; IMMUNOLOGY; LONGITUDINAL STUDY; LUNG; MICROBIOLOGY; PNEUMONIA, BACTERIAL; TIME FACTOR; TREATMENT FAILURE;

AGED; ANTI-BACTERIAL AGENTS; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LENGTH OF STAY; LONGITUDINAL STUDIES; LUNG; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 84927767348     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0165-y     Document Type: Article

References (40)

1. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000, 162:154-60. 10.1164/ajrccm.162.1.9907023, 10903235.
2. Ioanas M, Ferrer M, Cavalcanti M, Ferrer R, Ewig S, Filella X, et al. Causes and predictors of non-response to treatment of intensive care unit-acquired pneumonia. Crit Care Med. 2004, 32:938-45. 10.1097/01.CCM.0000114580.98396.91, 15071382.
3. Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, et al. Markers of treatment failure in hospitalised community-acquired pneumonia. Thorax. 2008, 63:447-52. 10.1136/thx.2007.086785, 18245147.
4. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis. Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007, 167:1655-63. 10.1001/archinte.167.15.1655, 17698689.
5. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001, 429:209-29. 10.1016/S0014-2999(01)01321-8, 11698042.
6. Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax. 1999, 54(Suppl 2):58-62. 10.1136/thx.54.2008.S58.
7. Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012, 2012:584262. doi:10.1155/2012/584262, 10.1155/2012/584262, 22778497.
8. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010, 36:612-20. 10.1007/s00134-009-1730-y, 19953222.
9. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis. 2005, 18:125-31. 10.1097/01.qco.0000160901.71813.fe, 15735416.
10. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009, 33:153-9. 10.1183/09031936.00054108, 18768577.
11. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improve outcomes with macrolides but not fluorquinolones. Chest. 2007, 131:466-73. 10.1378/chest.06-1426, 17296649.
12. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. International Pneumococcal study group. Combination antibiotic therapy lowers mortality among severily ill patients with pneumococcal pneumonia. Am J Respir Crit Care Med 2004, 170:440-4. 10.1164/rccm.200311-1578OC, 15184200.
13. Dwyer R, Ortqvist A, Aufwerber E, Henriques Normark B, Marrie TJ, Mufson MA, et al. Addition of a macrolide to a β-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006, 25:518-21. 10.1007/s10096-006-0183-2, 16896822.
14. Aspa J, Rajas O, Rodriguez DeCastro F, Huertas MC, Borderías L, Cabello FJ, et al. Pneumococcal Pneumonia in Spain study group. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006, 27:1010-9. 16455824.
15. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia. JAMA. 1998, 279:1452-7. 10.1001/jama.279.18.1452, 9600479.
16. Menéndez R, Torres A, Rodríguez de Castro F, Zalacaín R, Aspa J, Martín Villasclaras JJ, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004, 39:1783-90. 10.1086/426028, 15578400.
17. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997, 336:243-50. 10.1056/NEJM199701233360402, 8995086.
18. Alfageme I, Aspa J, Bello S, Blanquer J, Blanquer R, Borderías L, et al. Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2005, 41:272-89. 15919009.
19. Technical recommendations and guidelines for bronchoalveolar lavage. Report of the European Society of Pneumology Task Group. Eur Respir J. 1989;2:561-585.
20. Montón C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med. 1999, 27:1745-53. 10.1097/00003246-199909000-00008, 10507593.
21. Paats MS, Bergen IM, Hanselaar WE, van Zoelen ECG, Hoogsteden HC, Hendriks RW, et al. Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia. Eur Respir J. 2013, 41:1378-85. 10.1183/09031936.00060112, 23258791.
22. Moret I, Lorenzo MJ, Sarria B, Cases E, Morcillo E, Perpiñá M, et al. Increased lung neutrophil apoptosis and inflammation resolution in nonresponding pneumonia. Eur Respir J. 2011, 38:1158-64. 10.1183/09031936.00190410, 21436352.
23. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect. 2011, 63:187-99. 10.1016/j.jinf.2011.06.009, 21763343.
24. Meijvis SC, van de Garde EM, Rijkers GT, Bos WJ. Treatment with anti-inflammatory drugs in community-adquired pneumonia. J Intern Med. 2012, 272:25-35. 10.1111/j.1365-2796.2012.02554.x, 22583070.
25. Kovaleva A, Remmelts HH, Rijkers GT, Hoepelman AI, Biesma DH, Oosterheert JJ. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother. 2012, 67:530-40. 10.1093/jac/dkr520, 22190609.
26. Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm 2013, 2013:490346. doi:10.1155/2013/490346. Epub 2013 Dec 25, 10.1155/2013/490346, 24453422.
27. Demartini G, Esposti D, Marthyn P, Lapidari A, Fraschini F, Scaglione F. Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFN gamma and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother. 2004, 16:82-5. 10.1179/joc.2004.16.1.82, 15078004.
28. Spyridaki A, Raftogiannis M, Antonopoulou A, Tsaganos T, Routsi C, Baziaka F, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother. 2012, 56:3819-25. 10.1128/AAC.05798-11, 22564837.
29. Nakamura S, Yanagihara K, Araki N, Yamada K, Morinaga Y, Izumikawa K, et al. Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. Antimicrob Agents Chemother. 2010, 54:757-62. 10.1128/AAC.00524-09, 19949056.
30. Sanz MJ, Nabah YN, Cerdá-Nicolás M, O'Connor JE, Issekutz AC, Cortijo J, et al. Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression. Br J Pharmacol. 2005, 144:190-201. 10.1038/sj.bjp.0706021, 15665859.
31. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir Res. 2010, 11:90. 10.1186/1465-9921-11-90, 20591166.
32. Amado-Rodríguez L, González-López A, López-Alonso I, Aguirre A, Astudillo A, Batalla-Solís E, et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. Respir Res. 2013, 14:52. 10.1186/1465-9921-14-52, 23663489.
33. Anderson R, Steel HC, Cockeran R, von Gottberg A, de Gouveia L, Klugman KP, et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother. 2007, 59:224-9. 10.1093/jac/dkl479, 17218449.
34. Martínez JA, Horcajada JP, Almela M, Marco F, Soriano A, García E, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003, 36:389-95. 10.1086/367541, 12567294.
35. Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J. 2004, 11:589-93. 15611810.
36. Mufson MA, Stanek RJ. Revisiting combination antibiotic therapy for community-acquired invasive streptococcus pneumoniae pneumonia. Clin Infect Dis. 2006, 42:304-6. 10.1086/499110, 16355349.
37. Rodrigo C, Mckeever TM, Woodhead M, Lim WS. Single versus combination antibiotic therapy in adults hospitalized with community-acquired pneumonia. Thorax 2013, 68:493-5. 10.1136/thoraxjnl-2012-202296, 23076390.
38. Waterer GW, Rello J, Wunderink RG. Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med. 2011, 183:157-64. 10.1164/rccm.201002-0272CI, 20693379.
39. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of empiric antimicrobial therapy with β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care Med. 2005, 10:R8. 10.1186/cc3934.
40. Crisafulli E, Menéndez R, Huerta A, Martinez R, Montull B, Clini E, et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest. 2013, 143:1009-17. 10.1378/chest.12-1684, 23187314.